View clinical trials related to Leukemia, Myeloid, Acute.
Filter by:Single patient expanded access program to provide galinpepimut-S for eligible patients with AML or MDS who have no other treatment option.
The purpose of this registration is to list Managed Access Programs (MAPs) related to PKC4, Midostaurin.
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.